Drug intelligence / Profile preview

GBP-102

Development stage: Preclinical
Lead developer: University of Nottingham
Modality: Antibody-Based Therapeutics

Overview

GBP-102 is an antibody developed for the treatment of cancer. It is part of an Anti-CD55+ Antibody Program, which Genesis Biopharma acquired from Hamilton Atlantic. This acquisition provided Genesis Biopharma with foundational assets, including patents and know-how, to begin its new business focus on developing cancer therapeutics.

Targets

CD55 (Complement decay-accelerating factor)

Beyond the preview

Go deeper on GBP-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GBP-102.

Explore the full profile